Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries Ltd. (Sun Pharma) is the fourth largest specialty generic pharmaceutical company in the world with global revenues of over US$ 4.5 billion. Supported by more than 40 manufacturing facilities, we provide high-quality, affordable medicines, trusted by healthcare professionals and patients, to more than 100 countries across the globe. We produce a comprehensive, diverse and highly complementary portfolio of generic and specialty medicines targeting a wide spectrum of chronic and acute treatments. Our product portfolio includes generics, branded generics, speciality, difficult-to-make technology intensive products, over-the-counter (OTC), anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates. Our presence in more than 100 countries helps us in being responsive to local treatment needs while continually improving our global product offering.

Speciality Medications

Sun Pharma has built a portfolio of patent protected speciality medicines for global markets. Over the years, we have nurtured this evolving business through increased focus and investments. The key segments we are targeting are dermatology, ophthalmology and oncology. Our focus is on improving patient outcomes either by addressing unmet medical needs or by enhancing patient convenience through differentiated dosage forms. Our initiatives in this segment cover the entire value chain, from in-licensing early-to-late stage clinical candidates, as well as getting access to on-market patented products. Today, we are among the leading branded companies in the US with several speciality products launched in the country.

Generic Medications

We provide high quality generic and branded medicines at affordable costs to patients and doctors in more than 100 countries worldwide. Our products have the hallmark of technology-based differentiation and cover the full range of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams and liquids. The therapeutic segments covered by our portfolio of over 2000 molecules include psychiatry, anti-infectives, neurology, cardiology, orthopaedic, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. In several countries, Sun Pharma ranks among the leading companies in these therapy areas.

Over-the-Counter Medications

We provide a range of over-the-counter (OTC) / consumer healthcare products. Faringosept (sore throat), Revital (vitamins) and Volini (topical analgesics) are a few of our flagship OTC brands that are marketed in several countries globally. There are other category defining brands such as Coldact & Flustat (cold & flu), Brustan, Painamol & Paduden (analgesics), Aspenter, Aspacardin, Nudrate & Fortifikat (lifestyle OTCs), Gestid (digestives) and Chericof (cough).

Active Pharmaceutical Ingredients

We began producing Active Pharmaceutical Ingredients (APIs) in 1995 as a vital input in the manufacture of complex formulations to facilitate vertical integration. Today, our list of APIs exceeds 300 which is used in house as well as marketed to customers in over 60 countries. We manufacture APIs in 14 manufacturing facilities located in India, Hungary, US, Israel and Australia. Our product list includes generics and complex APIs that require isolated manufacturing areas like anti-cancers, peptides, steroids, sex hormones and controlled substances, including poppy-derived opiate raw materials that are primarily used in the manufacture of analgesics, sold as both Narcotic Raw Materials (NRM) and APIs. We offer bulk actives, intermediates and services for custom synthesis.

Anti Retro Viral Medications

We offer a wide range of WHO prequalified ARV medicines. Improving access and affordability is our key objective. We supply ARVs to various National AIDS treatment programs in Africa. In 2004, we signed up with the Clinton Health Access Initiative (CHAI) to help reduce the cost of the triple drug cocktail for consortium partners in Africa and other countries. Our portfolio comprises bio-equivalent ARV medicines and Active Pharmaceutical Ingredients (API) manufactured at our state-of-the-art WHO prequalified manufacturing facilities in India, a PIC/S approved manufacturing facility in South Africa and a facility in Russia. Indeed, with several first-line and second line Highly Active Antiretroviral Therapy (HAART) regimens in our portfolio, we hope to contribute significantly to combating HIV/AIDS.